Ultimovacs ASA (STU:7UM)
€ 0.2045 0 (0%) Market Cap: 7.12 Mil Enterprise Value: -3.75 Mil PE Ratio: 0 PB Ratio: 0.44 GF Score: 20/100

Q1 2023 Ultimovacs ASA Earnings Call Transcript

May 10, 2023 / 12:00PM GMT
Release Date Price: €11.24 (+5.24%)
Carlos de Sousa
Ultimovacs ASA - CEO

Good afternoon, everybody, and welcome to Ultimovacs' first-quarter 2023 results. As usually, I have with me Jens Bjørheim, our Chief Medical Officer; and Hans Vassgård Eid, our Chief Financial Officer.

You have the opportunity to ask questions and questions during the presentation. And we added to the ones that we have already received. And we will try to answer as many as possible after the presentation.

So if we move to the next slide. I have to show you the disclaimer. And in the next slide, for -- just to take in consideration that some people may not be so familiar with Ultimovacs, so I'll just give a quick introduction before moving in specific to the quarterly results.

So Ultimovacs is a clinical-stage biotech company. And we are developing a universal and off-the-shelf cancer vaccine that in a broad clinical program has the goal of showing that UV1 can be used in multiple cancer types and in combination with different classes of drugs.

And we target an enzyme that is expressed in 85% to 90% of cancers throughout all

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot